WR308633 | 1220911-09-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: WR308633
• 英文别名: 1-[2,8-Bis(trifluoromethyl)quinolin-4-yl]-2-butoxyethanol
• CAS: 1220911-09-0
• 化学式: C₁₇H₁₇F₆NO₂
• 分子量: 381.318
• InChiKey: ZBVPAPVVMYMMBS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  42.4
• 氢给体数：
  1
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  2-[2,8-二(三氟甲基)-4-喹啉基]环氧乙烷 、 正丁醇 在 sodium hydride 作用下， 以 四氢呋喃 为溶剂， 生成 WR308633
  参考文献：
  名称：

  Structure–activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum

  摘要：

  Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was constructed to identify early lead compounds that possess biological properties consistent with the target product pro. le for malaria chemoprophylaxis while reducing permeability across the blood-brain barrier. The library of 200 analogs resulted in compounds that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Herein we report selected chemotypes and the emerging structure activity relationship for this library of quinoline methanols. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2010.01.001

文献信息

• Compositions for the treatment of pancreatic cancer and uses thereof
  申请人：University of Florida Research Foundation, Incorporated

  公开号：US10835524B2

  公开（公告）日：2020-11-17

  The invention pertains to compositions comprising inhibitors of PI3K, AKT and/or mTOR, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (PI3K, AKT, mTOR, one or more 4-quinolinemethanols and various combinations thereof). The invention also provides a method of treating various forms of cancer, such as breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, brain cancer, lung cancer, non-small cell lung carcinoma, colorectal cancer, melanoma and/or pancreatic cancer.

  本发明涉及由 PI3K、AKT 和/或 mTOR 抑制剂、一种或多种 4-喹啉甲醇和药学上可接受的赋形剂组成的组合物。这些组合物可以包含亚治疗量的每种活性成分（PI3K、AKT、mTOR、一种或多种 4-喹啉甲醇及其各种组合）。本发明还提供了一种治疗各种形式癌症的方法，如乳腺癌、前列腺癌、多发性骨髓瘤、肝细胞癌、脑癌、肺癌、非小细胞肺癌、结直肠癌、黑色素瘤和/或胰腺癌。
• COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF
  申请人：University of Florida Research Foundation Incorporated

  公开号：US20180177776A1

  公开（公告）日：2018-06-28

  The invention pertains to compositions comprising inhibitors of PI3K, AKT and/or mTOR, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (PI3K, AKT, mTOR, one or more 4-quinolinemethanols and various combinations thereof). The invention also provides a method of treating various forms of cancer, such as breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, brain cancer, lung cancer, non-small cell lung carcinoma, colorectal cancer, melanoma and/or pancreatic cancer.
• [EN] COMPOSITIONS FOR THE TREATMENT OF CANCER AND USES THEREOF<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DU CANCER, ET LEURS UTILISATIONS
  申请人：UNIV FLORIDA

  公开号：WO2016209688A1

  公开（公告）日：2016-12-29

  The invention pertains to compositions comprising inhibitors of PI3K, AKT and/or mTOR, one or more 4-quinolinemethanols and a pharmaceutically acceptable excipient. These compositions can contain subtherapeutic amounts of each active ingredient (PI3K, AKT, mTOR, one or more 4-quinolinemethanols and various combinations thereof). The invention also provides a method of treating various forms of cancer, such as breast cancer, prostate cancer, multiple myeloma, hepatocyte carcinoma, brain cancer, lung cancer, non- small cell lung carcinoma, colorectal cancer, melanoma and/or pancreatic cancer.
• Structure–activity relationships amongst 4-position quinoline methanol antimalarials that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum
  作者：Erin Milner、William McCalmont、Jayendra Bhonsle、Diana Caridha、Dustin Carroll、Sean Gardner、Lucia Gerena、Montip Gettayacamin、Charlotte Lanteri、ThuLan Luong、Victor Melendez、Jay Moon、Norma Roncal、Jason Sousa、Anchalee Tungtaeng、Peter Wipf、Geoffrey Dow

  DOI：10.1016/j.bmcl.2010.01.001

  日期：2010.2

  Utilizing mefloquine as a scaffold, a next generation quinoline methanol (NGQM) library was constructed to identify early lead compounds that possess biological properties consistent with the target product pro. le for malaria chemoprophylaxis while reducing permeability across the blood-brain barrier. The library of 200 analogs resulted in compounds that inhibit the growth of drug sensitive and resistant strains of Plasmodium falciparum. Herein we report selected chemotypes and the emerging structure activity relationship for this library of quinoline methanols. Published by Elsevier Ltd.